Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.77 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.71 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.54 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | DNA2 | P51530 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977498 | 0.90 | KDM4E (0.67) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| Hydrochloric Acid SCHEMBL28606562 | 0.89 | KDM4E (0.65) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| SCHEMBL27599870 | 0.88 | BRPF1 (0.71) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| SCHEMBL25139503 | 0.83 | BRPF1 (0.69) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| SCHEMBL13715378 | 0.83 | BRPF1 (0.69) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| SCHEMBL3720911 | 0.83 | BRPF1 (0.69) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| SCHEMBL2036909 | 0.83 | NR4A2 (1.00) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| SCHEMBL13715439 | 0.83 | BRPF1 (0.69) | BRPF1NR4A2CNR2TRIM24TRIM33 | |
| SCHEMBL29415445 | 0.82 | HTT (0.59) | BRPF1NR4A2ALDH1A1HPGDHTT | |
| SCHEMBL2811213 | 0.82 | HTT (0.59) | BRPF1NR4A2ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306651-A | Indole 3-amide derivative and preparation method and application thereof | 山东大学 | 2025-01-14 | — | — | CN | disclosed |
| CN-119307565-A | Method for synthesizing L-7-methyl tryptophan by enzyme method | 浙江普洛生物科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-117756785-A | Preparation and application of N- (pyridine-2-yl) benzo [ b ] five-membered heterocycle-3-carboxamide structure compound | 江西中医药大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117603123-A | Novel indole HDAC6 small molecule inhibitor, preparation method and application | 郑州大学 | 2024-02-27 | — | — | CN | disclosed |
| CN-117603120-A | Preparation method and application of indole-3-fluoroketone compound | 平顶山学院 | 2024-02-27 | — | — | CN | disclosed |
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016007630-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | US | disclosed |
| WO-2009125923-A2 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108649-A1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | Korea Research Institute of Chemical Technology (KR) | 2009-10-14 | — | — | EP | disclosed |
| WO-2009060030-A1 | HETEROARYL-SUBSTITUTED 2-PYRIDINYLMETHYLAMINE DERIVATIVES | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2009-05-14 | — | — | WO | disclosed |
| EP-2058306-A1 | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives | SCHWARZ PHARMA AG (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-1998028292-A1 | NOVEL PIPERIDINE CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0328200-B1 | Five-membered ring systems with bonded azacyclic ring substituents | MERCK SHARP & DOHME (GB) | 1993-12-08 | — | — | EP | disclosed |
| US-5041456-A | Pharmaceutically useful 3-(indol-3-yl)-1,2,4-oxa- and thiadiazoles substituted in the 5-position by an amino containing group | MERCK SHARP & DOHME LTD. (GB) | 1991-08-20 | — | — | US | disclosed |
| US-4952587-A | PSYCHOLOGICAL DISORDERS, MIGRAINES, ALZHEIMER*S | MERCK SHARP & DOHME LTD. (GB) | 1990-08-28 | — | — | US | disclosed |
| EP-0328200-A1 | Five-membered ring systems with bonded azacyclic ring substituents | MERCK SHARP & DOHME LTD. (GB) | 1989-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121337-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK20, CDK2AP2 | BRPF1 1721/4885NR4A2 3309/4885CNR2 3600/4885 |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | HTR2C, HTR5A, HTR2A | BRPF1 3481/4885NR4A2 1506/4885CNR2 14/4885 |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | CHRNA7, CHRNA2, CHRNA5 | BRPF1 3390/4885NR4A2 638/4885CNR2 139/4885 |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | BRPF1 2834/4885NR4A2 358/4885CNR2 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.